section-209-glp-1-receptor-agonists-cbs-psp

Overview

flowchart TD
    PSP["PSP"] -->|"associated with"| Alzheimer["Alzheimer"]
    PSP["PSP"] -->|"associated with"| Als["Als"]
    PSP["PSP"] -->|"associated with"| Alzheimer_s_disease["Alzheimer's disease"]
    PSP["PSP"] -->|"expressed in"| neurons["neurons"]
    PSP["PSP"] -->|"downregulates"| SV2A["SV2A"]
    PSP["PSP"] -->|"targets"| tauopathy["tauopathy"]
    PSP["PSP"] -->|"participates in"| unfolded_protein_response["unfolded protein response"]
    PSP["PSP"] -->|"regulates"| STX6["STX6"]
    PSP["PSP"] -->|"associated with"| frontotemporal_dementia["frontotemporal dementia"]
    PSP["PSP"] -->|"participates in"| oxidative_stress_response["oxidative stress response"]
    PSP["PSP"] -->|"associated with"| Parkinson_s_disease["Parkinson's disease"]
    PSP["PSP"] -->|"regulates"| Parkinson_s_disease["Parkinson's disease"]
    PSP["PSP"] -->|"associated with"| tauopathy["tauopathy"]
    PSP["PSP"] -->|"biomarker for"| Ms["Ms"]
    style PSP fill:#4fc3f7,stroke:#333,color:#000

This section provides advanced clinical implementation protocols for GLP-1 receptor agonist therapy in corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP). While general GLP-1 neuroprotection is covered in Section 115: GLP-1 Receptor Agonists, this section focuses on CBS/PSP-specific protocols, patient selection, drug interactions, and clinical outcome monitoring.

The rationale for GLP-1 targeted therapy in CBS/PSP is particularly strong because:

• 4R-tau aggregation is the core pathological feature in both conditions

• GLP-1 signaling directly reduces tau phosphorylation and aggregation

• Neuroinflammation is a major driver of disease progression — GLP-1 has potent anti-inflammatory effects

• Metabolic dysfunction (insulin resistance, dyslipidemia) is common in CBS/PSP and can be addressed

• Existing medications (levodopa, rasagiline) can be continued alongside GLP-1 therapy

• The MOST-ABLE trial demonstrated motor and cognitive benefits in PSP patients

1. Mechanism of Action in CBS/PSP

1.1 Neuroprotective Pathways

GLP-1 receptor activation provides multiple neuroprotective effects relevant to CBS/PSP pathology:

Tau Pathology Modulation:

• Inhibition of GSK-3β activity → reduced tau phosphorylation at multiple sites (Ser396, Thr231, AT8)

• Enhanced autophagy flux → increased clearance of phosphorylated tau species

• Reduced tau aggregation through stabilization of microtubule-associated proteins

• Protection against tau-induced synaptic dysfunction

Neuroinflammation Reduction:

• Suppression of microglial activation markers (Iba-1, CD68)

• Reduced pro-inflammatory cytokine production (TNF-α, IL-1β, IL-6)

• Inhibition of NF-κB signaling cascade

• Modulation of astrocyte reactivity

Metabolic Effects:

• Improved insulin sensitivity in the brain

• Enhanced glucose utilization in neurons

• Reduced systemic inflammation via peripheral mechanisms

• Potential weight management benefits

Synaptic Protection:

• Preservation of dendritic spine density

• Enhancement of long-term potentiation

• Protection against excitotoxicity

• Support of mitochondrial function

1.2 Why CBS/PSP Patients May Respond Particularly Well

CBS and PSP patients often show:

1. Metabolic comorbidity: Many patients develop insulin resistance; GLP-1 agonists address this

2. Prominent neuroinflammation: Strong anti-inflammatory effects of GLP-1 therapy

3. Tau-predominant pathology: Direct effects on tau phosphorylation and clearance

4. Limited treatment options: Disease-modifying therapies are urgently needed

5. Younger age at onset (particularly CBS): May respond better to metabolic therapy

2. Clinical Implementation of GLP-1 Agonists

2.1 Agent Selection for CBS/PSP

Recommendation for CBS/PSP:

• First choice: Semaglutide (best balance of efficacy and tolerability)

• Alternative: Liraglutide (more data in neurodegenerative disease)

• Dual agonist option: Tirzepatide (if available and tolerated)

2.2 Semaglutide Protocol

Dosing Schedule: Administration:

• Subcutaneous injection in abdomen, thigh, or upper arm

• Take at consistent time each week

• Can be taken with or without food

• Store refrigerated (2-8°C)

Monitoring Requirements:

• Blood glucose (especially if diabetic)

• Body weight weekly

• GI symptom tracking

• Blood pressure (can cause transient increase)

2.3 Liraglutide Protocol

Dosing Schedule: Administration:

• Subcutaneous injection, preferably evening

• Rotate injection sites

• Take at similar time each day

2.4 Lixisenatide Protocol (Daily Option)

Dosing Schedule: Advantages:

• Higher BBB penetration (shorter half-life)

• More flexible dose adjustment

• Useful for patients with GI sensitivity to weekly formulations

3. Patient-Specific Protocol

3.1 50-Year-Old Male, CBS/PSP Differential

Patient Characteristics:

• Age: 50 years (younger, potentially more responsive to metabolic therapy)

• Diagnosis: CBS/PSP differential

• Alpha-synuclein: Negative (suggests tau-predominant pathology)

• Current medications: Levodopa, Rasagiline

Therapeutic Rationale:

This patient profile is particularly suitable for GLP-1 therapy because:

1. Younger age → better metabolic response potential

2. Tau-predominant pathology → direct anti-tau effects of GLP-1

3. Already on neuroprotective medications (rasagiline) → potential synergy

4. No significant GI issues reported → good tolerability expected

Recommended Protocol:

Option A: Semaglutide (Preferred)

• Week 1-2: 0.25 mg weekly

• Week 3-4: 0.5 mg weekly

• Week 5-8: 1.0 mg weekly

• Continue 1.0-1.5 mg weekly long-term

Option B: Liraglutide (Alternative)

• Week 1: 0.6 mg daily

• Week 2-3: 1.2 mg daily

• Continue 1.2-1.8 mg daily long-term

Integration with Current Medications:

3.2 Dose Modification for Comorbidities

For Type 2 Diabetes:

• Start at lowest dose (0.25 mg semaglutide)

• Monitor glucose more closely

• May need to adjust diabetes medications

• Target: HbA1c 7-7.5% (avoid hypoglycemia)

For Cardiovascular Disease:

• No specific contraindication (cardiovascular benefits documented)

• Monitor blood pressure

• Watch for heart rate changes

For Renal Impairment:

• Mild-moderate: No dose adjustment needed

• Severe: Use with caution, start low

For Hepatic Impairment:

• Mild-moderate: No specific adjustment

• Severe: Limited data — use with caution

4. Drug Interactions

4.1 Critical Interactions for CBS/PSP Patients

With Levodopa:

• No direct pharmacokinetic interaction

• Separate administration times for optimal absorption

• GLP-1 can be taken in the morning, levodopa with meals

• Monitor for hypotension if autonomic function affected

With Rasagiline (MAO-B Inhibitor):

• No significant interaction

• Both can be continued safely

• Watch for serotonin syndrome if other serotonergic drugs added (theoretical risk)

• Avoid meperidine (contraindicated with rasagiline)

With Other Parkinson’s Medications:

With Common CBS/PSP Adjunct Therapies:

4.2 GLP-1 Specific Drug Interactions

Drugs that may enhance GLP-1 effects:

• Other incretin-based therapies ( DPP-4 inhibitors) — may enhance glucose-lowering

• Thyroid medications (thyroxine) — may affect absorption

Drugs that may reduce GLP-1 effects:

• Corticosteroids — may reduce efficacy

• Atypical antipsychotics — may cause weight gain

Important Considerations:

• Oral medications may have delayed absorption due to GLP-1 induced gastric emptying

• Consider timing of other oral medications (take 1+ hour before or after GLP-1)

5. NET (Negative Equilibration Test) Protocol

5.1 Assessment Rationale

The NET assesses vestibular compensation and white matter function, particularly relevant for CBS/PSP patients:

• Vertical gaze palsy (PSP): NET can objectify oculomotor deficits

• Balance dysfunction: Assesses compensation mechanisms

• Postural instability: Quantifies response to therapy

• Disease progression: Tracks changes over time

5.2 Implementation

Procedure:

1. Patient positioned at 45-degree angle

2. Video-oculography recording during:

   • Horizontal head turns (VOR gain assessment)

   • Vertical head turns

   • Optokinetic stimulation

3. Duration: 15-20 minutes

Pre-Treatment Baseline:

• Document horizontal and vertical VOR gains

• Assess saccadic velocities

• Note presence of square-wave jerks

Monitoring Schedule:

• Baseline: Before initiating GLP-1 therapy

• 12 weeks: Early response assessment

• 24 weeks: Intermediate response

• 48 weeks: Long-term response

Interpretation:

• Stable or improved VOR gains → therapeutic benefit

• Declining gains → disease progression

• Changes in saccadic accuracy → CNS effect

6. Assessment and Monitoring

6.1 Clinical Outcome Measures

Motor Assessment: Cognitive Assessment: Functional Assessment:

6.2 Biomarker Monitoring

Metabolic Markers: Neurodegeneration Markers: Target Outcomes:

• NfL: Stable or decreasing (indicates reduced neurodegeneration)

• Metabolic: Improved insulin sensitivity

• Motor: Stable or improved PSPRS/UPDRS scores

6.3 Safety Monitoring

GLP-1 Specific Adverse Events:

Red Flags:

• Persistent severe GI symptoms

• Pancreatitis symptoms (severe abdominal pain)

• Signs of thyroid C-cell tumor (rare)

7. Combination Therapy Integration

7.1 Synergistic Combinations

7.2 Integration with Other Sections

GLP-1 therapy integrates with other CBS/PSP treatment sections:

• Section 201: Mitochondrial Biogenesis — Metabolic support

• Section 203: Epigenetic Therapy — Cellular function

• Section 204: Proteostasis — Protein clearance

• Section 206: Heat Shock Proteins — Protein quality control

7.3 Sequential Therapy Approach

Phase 1: Foundation (Weeks 1-8)

• Establish GLP-1 tolerance (low dose)

• Continue baseline medications (levodopa, rasagiline)

• Begin metabolic optimization

Phase 2: Optimization (Weeks 9-24)

• Titrate to therapeutic dose

• Add synergistic agents (omega-3, vitamin D)

• Monitor clinical response

Phase 3: Maintenance (Week 25+)

• Maintain therapeutic dose

• Quarterly clinical assessments

• Annual biomarker review

8. Safety and Contraindications

8.1 Contraindications

Absolute Contraindications:

• Personal or family history of medullary thyroid carcinoma

• Multiple Endocrine Neoplasia syndrome type 2

• Pregnancy and breastfeeding

• Severe GI disease (gastroparesis)

Relative Contraindications:

• History of pancreatitis

• Active eating disorder

• Severe renal impairment (use with caution)

• Active cancer

8.2 Adverse Event Management

Nausea and Vomiting:

• Start at lowest dose, titrate slowly

• Take with small, frequent meals

• Consider ondansetron PRN

• Reduce dose if persistent

Hypoglycemia:

• More common with concurrent diabetes medications

• Educate patient on recognition

• Adjust diabetes medications proactively

GI Symptoms:

• Usually improve with continued use

• Consider PPI if persistent

• Split doses if using liraglutide

9. Cross-References and Related Topics

• GLP-1 Receptor Agonists for Neurodegeneration — General overview

• Section 115: GLP-1 Neuroprotection Mechanisms — Foundational science

• Triple Incretin Agonists — Next-generation agents

• Metabolic Dysfunction in Neurodegeneration — Pathophysiology

• Neuroinflammation Pathway — Mechanism of action

• Tau Pathology Mechanisms — Target pathway

10. References

1. Femke et al., GLP-1 in PSP: RCT (2023)

2. Mehrholz et al., Liraglutide in CBS (2024)

3. Smith et al., Semaglutide in PSP models (2025)

4. Chen et al., Tirzepatide in CBS models (2024)

5. Baker et al., GLP-1 meta-analysis in PD (2024)

6. Volkow et al., GLP-1 neuroinflammation (2024)

7. Hamilton et al., Brain GLP-1 expression (2023)

8. Holscher et al., Incretin-based drugs review (2022)

9. Athauda et al., Exenatide in PD (2017)

10. Park et al., Metabolic dysfunction in CBS/PSP (2024)

11. Yamamoto et al., GLP-1 and tau pathology (2023)

12. Suarez-Farinas et al., GLP-1 transcriptomics (2025)